奕瑞电子科技集团股份有限公司 关于开立募集资金理财产品专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 9 月 28 召 开第三届董事会第十九次会议和第三届监事会第十六次会议，审议通过了《关于 使用暂时闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币 11 亿元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、风 险等级低的保本型产品（包括但不限于保本型理财产品、结构性存款、定期存款、 大额存单、七天通知存款等），使用期限自公司董事会审议通过之日起 12 个月内 有效。在前述额度和期限内，资金可循环滚动使用。具体内容详见公司于同日在 上海证券交易所网站（www.sse.com.cn）披露的《奕瑞电子科技集团股份有限公 司关于使用暂时闲置募集资金进行现金管理的公告》（公告编号：2025-071）。 一、开立募集资金理财产品专用结算账户的情况 | 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-0 ...

Group 1 - The core viewpoint of the news is that Yirui Technology's stock has seen a significant increase, with a rise of 5.15% to 117.46 CNY per share, and a total market capitalization of 23.518 billion CNY [1] - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and services of digital X-ray detectors [1] - The main revenue composition of Yirui Technology includes 81.21% from detector sales, 7.66% from core component sales, 5.89% from solution/technical services, 4.57% from accessory sales, and 0.66% from leasing [1] Group 2 - From the perspective of fund holdings, Yirui Technology is a significant investment for the Huatai-PineBridge Fund, with the Huatai-PineBridge Private Vitality Mixed Fund holding 990,000 shares, representing 3.63% of the fund's net value [2] - The Huatai-PineBridge Private Vitality Mixed Fund has achieved a year-to-date return of 55.49%, ranking 761 out of 8173 in its category, and a one-year return of 91.48%, ranking 859 out of 7996 [2] - The fund manager, Ma Xiang, has been in position for 9 years and 200 days, with the fund's total asset size at 10.726 billion CNY and a best return of 266.03% during his tenure [3]

Investment Rating - The report recommends focusing on leading companies in various segments of the high-value consumables and medical device sectors, indicating a positive outlook for recovery and growth in these areas [4][30]. Core Insights - High-value consumables have begun to recover from the impacts of centralized procurement, with leading companies regaining profitability levels seen before the procurement initiatives [4][32]. - The medical device and IVD sectors are expected to show signs of recovery, with significant improvements anticipated in financial performance by Q3 2025 for device companies and by Q4 2025 for IVD companies [4][30]. - The report highlights specific high-growth segments, including vascular intervention, orthopedics, and IVD, suggesting that these areas will continue to attract investment due to their growth potential and market dynamics [4][30]. Summary by Sections Medical Devices - The medical device sector is projected to experience a revenue decline in 2024, with a further drop of -5.18% expected in the first half of 2025, but recovery is anticipated thereafter [9][12]. - Despite revenue challenges, the overall gross margin and net profit margin have remained stable, with R&D expenses increasing from approximately 7% pre-pandemic to around 10% currently [10][12]. - Companies in the imaging equipment segment are expected to see improved performance in Q3 2025 as inventory issues are resolved and new procurement projects are executed [13][18]. High-Value Consumables - The high-value consumables sector has shown revenue growth in the first half of 2025, indicating a recovery from previous declines, with profit margins returning to levels seen in 2021 [32][33]. - Specific segments such as vascular intervention and orthopedics are highlighted for their resilience and growth potential, with companies like Huatai Medical and Weigao Orthopedics showing significant revenue increases [38][43]. IVD and Other Segments - The IVD sector is expected to see improvements by Q4 2025, with overall industry recovery projected for the first half of 2026 [4][30]. - The report emphasizes the importance of innovation and market expansion for companies in the rehabilitation and home medical device sectors, with firms like Sanofi and Kefu Medical showing strong growth despite market challenges [24][26].

Market Performance - The Medical Health Index (980016) closed at 7021.34 points, down 1.08%, with a trading volume of 33.906 billion yuan and a turnover rate of 1.07% [1] - Among the index constituents, 5 stocks rose while 45 stocks fell, with Yirui Technology leading the gainers at 1.82% and Changchun High-tech leading the decliners at 3.91% [1] Key Constituents - The top ten constituents of the Medical Health Index include: - WuXi AppTec (13.58% weight) at 108.75 yuan, up 1.23% with a market cap of 320.976 billion yuan - Hengrui Medicine (10.87% weight) at 69.65 yuan, down 2.03% with a market cap of 462.281 billion yuan - Mindray Medical (8.17% weight) at 235.00 yuan, down 1.18% with a market cap of 284.924 billion yuan - United Imaging Healthcare (4.14% weight) at 147.90 yuan, down 1.40% with a market cap of 121.893 billion yuan - Other notable constituents include Pianzai Shou, Yier Eye Hospital, Kelun Pharmaceutical, Xinhecheng, Fosun Pharma, and Yixiao Aoshi [1] Capital Flow - The Medical Health Index constituents experienced a net outflow of 2.29 billion yuan from institutional investors, while retail investors saw a net inflow of 2.013 billion yuan [3] - Notable capital flows include: - Mindray Medical with a net inflow of 98.789 million yuan from institutional investors and a net outflow of 10.5 million yuan from speculative funds - Changchun High-tech with a net inflow of 67.986 million yuan from institutional investors and a significant net outflow from speculative funds [3]

证券之星消息，9月18日，医疗健康R（480016）指数报收于8279.99点，跌0.21%，成交485.59亿元，换 手率1.57%。当日该指数成份股中，上涨的有19家，长春高新以5.19%的涨幅领涨，下跌的有31家，奕瑞 科技以2.94%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： | 医疗健康R指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 13.58% | 107.43 | -1.70% | | 3170.80 | 医药生物 | | sh600276 | 恒瑞医药 | 10.87% | 71.09 | 1.37% | | 4718.39 | 医药生物 | | sz300760 | 迈瑞医疗 | 8.17% | 237.80 | -0.66% | | 2883.19 | 医药生物 | | sh688271 | 联影医疗 | 4.14% | 150.00 ...

9月18日，奕瑞科技盘中下跌2.02%，截至13:46，报111.70元/股，成交2.48亿元，换手率1.09%，总市值 223.64亿元。 奕瑞科技所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：口腔医疗、专精特新、 融资融券、中盘、增持回购等。 截至6月30日，奕瑞科技股东户数6990.00，较上期增加21.67%；人均流通股28643股，较上期增加 15.02%。2025年1月-6月，奕瑞科技实现营业收入10.67亿元，同比增长3.94%；归母净利润3.35亿元，同 比增长8.82%。 分红方面，奕瑞科技A股上市后累计派现7.89亿元。近三年，累计派现5.57亿元。 机构持仓方面，截止2025年6月30日，奕瑞科技十大流通股东中，华宝中证医疗ETF（512170）位居第 九大流通股东，持股392.60万股，为新进股东。景顺长城新能源产业股票A类（011328）退出十大流通 股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出679.79万元，特大单买入1264.27万元，占比5.10%，卖出3179.83万元， 占比12.83%；大单买入5865.77万元，占比23.67%，卖出 ...

Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 789 million yuan, with 557 million yuan distributed over the past three years [3] Stock Market Activity - On September 17, Yirui Technology's stock price decreased by 2.02%, trading at 112.33 yuan per share, with a total market capitalization of 22.491 billion yuan [1] - The stock has seen a year-to-date increase of 66.23%, with a 1.95% rise over the last five trading days, 1.98% over the last twenty days, and 24.88% over the last sixty days [1] - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per shareholder, up 15.02% [2] Institutional Holdings - As of June 30, 2025, the ninth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 3.926 million shares as a new shareholder, while the Invesco Great Wall New Energy Industry Stock A Class has exited the top ten circulating shareholders [3]

Core Points - The Medical Health R Index (480016) closed at 8278.77 points, down 0.33%, with a trading volume of 31.765 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 18 stocks rose while 31 fell, with Yirui Technology leading the gainers at a 4.4% increase and Zexin Pharmaceutical leading the decliners at a 5.37% decrease [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.58% and a market cap of 315.96 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 10.87% and a market cap of 458.96 billion yuan [1] - Mindray Medical (sz300760) with a weight of 8.17% and a market cap of 290.50 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.14% and a market cap of 126.08 billion yuan [1] - Other notable constituents include Pianzai Shou (sh600436), Yierfu Technology (sz300015), Kelun Pharmaceutical (sz002422), New Hope Liuhe (sz002001), Fosun Pharma (sh600196), and East China Pharmaceutical (sz000963) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 1.638 billion yuan, while retail investors saw a net inflow of 1.098 billion yuan [1] - Notable capital flows include: - Kailai Ying (002821) with a main fund net inflow of 101 million yuan [2] - Mindray Medical (300760) with a main fund net inflow of approximately 90.77 million yuan [2] - Yuyue Medical (002223) with a main fund net inflow of 24.60 million yuan [2]

Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service revenue (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] Stock Performance - On September 15, Yirui Technology's stock price decreased by 2.05%, trading at 109.20 yuan per share, with a market capitalization of 21.864 billion yuan [1] - The stock has seen a year-to-date increase of 61.60%, a decline of 7.84% over the last five trading days, a slight increase of 1.10% over the last 20 days, and a rise of 24.67% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up by 15.02% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF is a new entrant holding 3.926 million shares, while Jingshun Changcheng New Energy Industry Stock A has exited the list [3] Market Position - Yirui Technology operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as oral healthcare, specialized and innovative enterprises, mid-cap stocks, margin financing, and share buybacks [1]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-066 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 奕瑞电子科技集团股份有限公司（以下简称"公司"）于2025年9月12日召 开第三届董事会第十八次会议、第三届监事会第十五次会议，审议通过了《关于 作废部分已授予尚未归属的2023年限制性股票及注销2023年部分股票期权的议 案》，根据《上海奕瑞光电子科技股份有限公司2023年限制性股票与股票期权激 励计划（草案）》（以下简称"《激励计划》"或"本激励计划"）的有关规定， 现将有关事项说明如下： 一、本激励计划已履行的决策程序和信息披露情况 1、2023年10月13日，公司召开第二届董事会第二十三次会议，审议通过了 《关于公司<2023年限制性股票与股票期权激励计划（草案）>及其摘要的议案》 《关于公司<2023年限制性股票与股票期权激励计划实施考核管理办法>的议案》 以及《关于提请股东大会授权董事会办理公司激励计划相关事宜的议案》等议 案。公司独立董事就本激励计划是否有利于公司的持续发展及是否存 ...